Sotorasib's Accelerated Approval: Wrong Dose and Indication
- PMID: 40079943
- DOI: 10.1001/jamaoncol.2025.0039
Sotorasib's Accelerated Approval: Wrong Dose and Indication
Plain language summary
This Viewpoint reviews the accelerated approval process and lack of postapproval studies to verify its benefit as it applied to sotorasib, a treatment for non–small cell lung cancer with the KRASg12c mutation, and recommends measures to ensure confirmatory follow-up studies.
LinkOut - more resources
Full Text Sources